...
机译:患者报告的结果来自开放标签随机阶段III选择BC试验评估转移乳腺癌的一线S-1治疗
Biostatistics Division Clinical Research Support Center The University of Tokyo Hospital Tokyo;
Department of Biomedical Sciences College of Life Sciences Ritsumeikan University Kusatsu;
Department of HealthWelfare Services National Institute of Public Health Wako;
Department of Biostatistics Division of Health SciencesNursing Graduate School of Medicine The;
Biostatistics Division Clinical Research Support Center The University of Tokyo Hospital Tokyo;
Department of Breast Surgery National Hospital Organization Sendai Medical Center Sendai;
Department of BreastEndocrine Surgery Okayama University Hospital Okayama;
Department of HealthWelfare Services National Institute of Public Health Wako;
Department of Integrated ScienceEngineering for Sustainable Society Faculty of ScienceEngineering;
Department of BreastMedical Oncology National Cancer Center Hospital East Kashiwa Japan;
Adjuvant chemotherapy; Chemotherapy-induced peripheral neuropathy; Clinical trials; Health-related quality of life; Metastatic breast cancer;
机译:患者报告的结果来自开放标签随机阶段III选择BC试验评估转移乳腺癌的一线S-1治疗
机译:紫杉烷与S-1作为转移性乳腺癌的一线化疗(SELECT BC):一项开放性,非劣效性,随机3期试验
机译:由转移乳腺癌患者的EQ-5D测量的长期健康状况:在随机阶段III中的一线口服S-1和紫杉烷疗法的比较选择BC试验
机译:Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
机译:通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理:随机对照试验
机译:日本一线转移性乳腺癌治疗采用S-1疗法的成本-效果分析:来自随机III期SELECT BC试验的结果
机译:通过EQ-5D在转移性乳腺癌患者中测得的长期健康状况:在SELECT III SELECT随机试验中比较一线口服S-1和紫杉烷疗法